EXEL: CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans
Category: Business
Share
Archive
Like
CABO's growth is driven by RCC and NET, with exclusivity expected until 2031 and a $3B target. Zanza is poised for immediate CRC launch, supported by strong clinical data and expanded sales force. Strategic focus includes pipeline expansion, business development, and balanced capital allocation.
Based on Exelixis, Inc. [EXEL] Wells Fargo 21st Annual Healthcare Conference Audio Transcript — Sep. 8 2026
A note on cookies
Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.
Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.
(0)Comments